omeprazole, amoxicillin, and rifabutin · Talicia
Small molecule
Also known as RHB-105
Evidence outlook
Approved: Helicobacter pylori Infection
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Helicobacter pylori infection (Talicia, omeprazole magnesium, amoxicillin and rifabutin)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ERADICATE Hp2 NCT03198507 · Helicobacter Pylori Infection, Dyspepsia This was a randomized, triple-blind, active-controlled trial with 455 participants, and its primary clinical endpoint—eradication of H. pylori confirmed by urea breath testing—was statistically significantly better with RHB-105 than with the comparator. These results provide strong evidence for the tested combination in this study population. Registry: NCT03198507 | 3 | Number of Participants With Eradication of H. Pylori (43-71 days after initiation of treatment) 2018-10-24 | Number of Participants With Eradication of H. Pylori (43-71 days after initiation of treatment): RHB-105 191 Participants | Active Comparator 131 Participants | Reliable signal | link ↗ |
View 1 more trial
ERADICATE Hp NCT01980095 · Dyspepsia, Helicobacter Pylori Infection The trial was randomized, triple-blind, placebo-controlled, and included 119 participants. Its primary clinical endpoint—H. pylori eradication confirmed by urea breath testing—was met: 59/66 participants receiving RHB-105 versus 1/37 receiving placebo achieved eradication, with a reported one-sample Z-test p=0.001 against the prespecified 70% benchmark. Registry: NCT01980095 | 3 | The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing (28-56 days after completion of treatment) 2015-06 | The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing (28-56 days after completion of treatment): RHB-105 — H. pylori eradication success: 59 Participants; H. pylori eradication failure: 7 Participants | Placebo — H. pylori eradication success: 1 Participants; H. pylori eradication failure: 36 Participants | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Helicobacter pylori Infection: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Omeprazole, Amoxicillin, And Rifabutin (Talicia): this drug | Approved | Small molecule | H. pylori eradication (PPI + amoxicillin + rifabutin) | Reliable signal | NCT03198507: Number of Participants With Eradication of H. Pylori (43-71 days after initiation of treatment): RHB-105 191 Participants | Active Comparator 131 Participants NCT01980095: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing (28-56 days after completion of treatment): RHB-105 — H. pylori eradication success: 59 Participants; H. pylori eradication failure: 7 Participants | Placebo — H. pylori eradication success: 1 Participants; H. pylori eradication failure: 36 Participants | |
| Esomeprazole (Nexium) | Approved | Small molecule | H+/K+-ATPase (gastric proton pump) | not yet graded | No reviewed efficacy summary in this indication | |
| Rabeprazole (Aciphex) | Approved | Small molecule | H+/K+-ATPase (gastric proton pump) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.